Biosort Secures More Than NOK 100 Million to Commercialize Individual-Based Lice Control

Biosort Secures More Than NOK 100 Million to Commercialize Individual-Based Lice Control

Biosort, best known for the development license project iFarm, has secured more than NOK 100 million from a strong group of aquaculture and technology investors to bring its individual-based lice control system to market.

Investors include Grieg Kapital, Hatch Blue, IVC, Farvatn, and Futurum Ventures, together with existing owners.

The capital will support final development and market introduction of Biosort’s next-generation, lice control technology.  The system is designed to efficiently remove lice at an early stage, preventing uncontrolled lice population growth and reducing the need for full-pen interventions.

“This funding takes us from development into commercial sales. Our focus is simple: continuous lice removal to suppress lice development and greatly reduce needs for well-boat treatments. The goal is improved welfare, lower mortality, better biological control, and ultimately making fish thrive.” said Geir Stang Hauge, CEO of Biosort.

Founded in 2010, Biosort has developed advanced machine vision, AI, and FishID technology capable of identifying and tracking individual salmon. The system now combines early lice removal with data on individual fish.

“We have followed Biosort for several years and are impressed by the team and their technology. Sea lice remain one of the greatest challenges in salmon farming, and Biosort’s approach has the potential to improve both lice management and fish health. We are excited to support the company as it moves into commercialization,” said Stian Grieg, Investment Manager at Grieg Kapital.

“There is a clear shift in the salmon industry toward stronger focus on fish health and greater adoption of new technology. Through Blue Revolution Fund, we invest in next-generation aquaculture solutions that improve health and sustainability. Together with a strong and experienced investor consortium, we believe Biosort is well positioned to contribute to the next phase of salmon farming,” said Carsten Krome, Managing Partner at Hatch Blue.

‍

Related posts

Hatch Blue backs Hadl: AI diagnostics for animal health and plankton measurement

Hatch Blue backs Hadl: AI diagnostics for animal health and plankton measurement

Hadl surfaces early signals of imbalance, stress and disease in near real time, so intervention can start before losses begin.
The North Atlantic Blue BioTech Summit returns to Portland, Maine, in March 2027

The North Atlantic Blue BioTech Summit returns to Portland, Maine, in March 2027

After a sold-out first edition, the 2027 summit brings innovators, investors and global brands together around transforming the ocean’s immense diversity into valuable products. Registrations of interest are now open.
New Hatch Blue report maps barriers and opportunities for investment in U.S. aquaculture

New Hatch Blue report maps barriers and opportunities for investment in U.S. aquaculture

The report examines the barriers to investment, identifies emerging commercial opportunities, and takes a closer look at five regional aquaculture hubs: Hawaiʻi, Alaska, California, Maine, and Washington.
Hatch Blue and UMITO Partners partner to launch a first-of-its-kind aquaculture innovation studio in Japan

Hatch Blue and UMITO Partners partner to launch a first-of-its-kind aquaculture innovation studio in Japan

A new strategic partnership will connect Japan’s most promising aquaculture innovators with domestic and global corporations, investors and researchers, with a flagship program planned for 2027.